NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Pegvisomant

Last Revision: October 31, 2018.

Estimated reading time: 1 minute

CASRN: 218620-50-9

Drug Levels and Effects

Summary of Use during Lactation

Limited data indicate that pegvisomant is poorly excreted into breastmilk. Because pegvisomant is not orally absorbed, it is unlikely to adversely affect the breastfed infant.

Drug Levels

A woman was being treated during pregnancy for acromegaly with subcutaneous pegvisomant at a dosage that was progressively escalated from 15 mg to 25 mg daily during the course of pregnancy, and presumably postpartum. At an unreported time postpartum, pegvisomant was not detectable (<50 mcg/L) in breastmilk. The patient's breastmilk growth hormone concentration was 0.6 mcg/L compared to <0.1 mcg/L in 3 breastmilk samples from normal healthy mothers.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Brian SR, Bidlingmaier M, Wajnrajch MP et al. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab. 2007;92:3374-7. [PubMed: 17595256]

Substance Identification

Substance Name

Pegvisomant

CAS Registry Number

218620-50-9

Drug Class

  • Breast Feeding
  • Human Growth Hormone Analogues and Derivatives
  • Growth Hormone Receptor Antagonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Teicoplanin[Drugs and Lactation Database (...]
    Review Teicoplanin
    . Drugs and Lactation Database (LactMed). 2006
  • Review Miglitol[Drugs and Lactation Database (...]
    Review Miglitol
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dabigatran[Drugs and Lactation Database (...]
    Review Dabigatran
    . Drugs and Lactation Database (LactMed). 2006
  • Review Butorphanol[Drugs and Lactation Database (...]
    Review Butorphanol
    . Drugs and Lactation Database (LactMed). 2006
  • Review Peginterferon Alfa[Drugs and Lactation Database (...]
    Review Peginterferon Alfa
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...